Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H L Zaaijer

Showing results (21-30 of 99) with videos related to

Pageof 10
Sort By:
Transplantation Proceedings|October 1, 1996
Risk of virus transmission by tissue, blood, and plasma productsP N Lelie, H L Zaaijer, H T Cuypers
Lancet (London, England)|September 12, 1992
Seroprevalence of hepatitis E in The NetherlandsH L Zaaijer, M F Yin, P N Lelie
Transfusion Medicine (Oxford, England)|November 15, 2013
Positive HBV-NAT in a blood donor 11 years after HBV vaccinationA Zeinali Lathori, H L Zaaijer, W M Smid
Journal of Medical Virology|January 1, 1997
Temporary seronegativity in a human immunodeficiency virus type 1-infected manH L Zaaijer, M H Bloemer, P N Lelie
Nederlands Tijdschrift Voor Geneeskunde|April 30, 1999
[Whipple's disease]H L Zaaijer, P H Savelkoul, C M Vandenbroucke-Grauls
Vox Sanguinis|July 11, 2012
The yield of temporary exclusion of blood donors, exposed to emerging infections abroadR W Lieshout-Krikke, H L Zaaijer, F J Prinsze
Nederlands Tijdschrift Voor Geneeskunde|August 9, 1997
[Infection with T-lymphotropic virus in Dutch blood donors, 1993-1996]H L Zaaijer, P N Lelie, C L van der Poel
Journal of Medical Virology|May 1, 1993
Hepatitis A antibody titres after infection and immunization: implications for passive and active immunizationH L Zaaijer, A Leentvaar-Kuijpers, H Rotman, et al.
Epidemiology and Infection|January 8, 2005
Parvovirus B19 viraemia in Dutch blood donorsH L Zaaijer, M H G M Koppelman, C P Farrington
Journal of Viral Hepatitis|October 13, 2015
Identification of FDA-approved drugs that target hepatitis B virus transcriptionM A A van de Klundert, H L Zaaijer, N A Kootstra
Pageof 10

Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
Transplantation Proceedings|October 1, 1996
Risk of virus transmission by tissue, blood, and plasma productsP N Lelie, H L Zaaijer, H T Cuypers
Lancet (London, England)|September 12, 1992
Seroprevalence of hepatitis E in The NetherlandsH L Zaaijer, M F Yin, P N Lelie
Transfusion Medicine (Oxford, England)|November 15, 2013
Positive HBV-NAT in a blood donor 11 years after HBV vaccinationA Zeinali Lathori, H L Zaaijer, W M Smid
Journal of Medical Virology|January 1, 1997
Temporary seronegativity in a human immunodeficiency virus type 1-infected manH L Zaaijer, M H Bloemer, P N Lelie
Nederlands Tijdschrift Voor Geneeskunde|April 30, 1999
[Whipple's disease]H L Zaaijer, P H Savelkoul, C M Vandenbroucke-Grauls
Vox Sanguinis|July 11, 2012
The yield of temporary exclusion of blood donors, exposed to emerging infections abroadR W Lieshout-Krikke, H L Zaaijer, F J Prinsze
Nederlands Tijdschrift Voor Geneeskunde|August 9, 1997
[Infection with T-lymphotropic virus in Dutch blood donors, 1993-1996]H L Zaaijer, P N Lelie, C L van der Poel
Journal of Medical Virology|May 1, 1993
Hepatitis A antibody titres after infection and immunization: implications for passive and active immunizationH L Zaaijer, A Leentvaar-Kuijpers, H Rotman, et al.
Epidemiology and Infection|January 8, 2005
Parvovirus B19 viraemia in Dutch blood donorsH L Zaaijer, M H G M Koppelman, C P Farrington
Journal of Viral Hepatitis|October 13, 2015
Identification of FDA-approved drugs that target hepatitis B virus transcriptionM A A van de Klundert, H L Zaaijer, N A Kootstra
Pageof 10